ALP
AlphaTON Capital Corp.
NASDAQ · Healthcare · Biotechnology · VG
$0.10
−13.74%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 97.0K | 97.0K | — | — | — |
| Cost of Revenue | — | — | 35.0K | 54.0K | 1.0K |
| Gross Profit | 97.0K | 97.0K | (35.0K) | (54.0K) | (1.0K) |
| Operating Expenses | |||||
| R&D Expense | 2.7M | 2.8M | 3.1M | 12.5M | 8.2M |
| SG&A Expense | 21.7M | 20.2M | 4.3M | 5.7M | 8.4M |
| General & Admin Expense | 21.7M | 20.2M | 4.3M | 5.7M | 8.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 193.0K | 193.0K | — | — | — |
| Total Operating Expenses | 24.6M | 23.2M | 7.4M | 18.2M | 16.6M |
| Cost and Expenses | 24.6M | 23.2M | 7.4M | 18.3M | 16.6M |
| Operating Income (EBIT) | (24.5M) | (23.1M) | (7.4M) | (18.3M) | (16.6M) |
| Non-Operating | |||||
| Interest Income | 5.0K | — | 89.0K | 274.0K | 217.0K |
| Interest Expense | 1.0M | 1.0M | 3.0K | 32.0K | 9.0K |
| Net Interest Income | (1.0M) | (1.0M) | 86.0K | 242.0K | 208.0K |
| Other Non-Op Income/Expense | (18.9M) | (15.5M) | 637.0K | (67.4M) | (105.9M) |
| Non-Operating Income (excl Interest) | 8.3M | (14.5M) | (640.0K) | 54.0K | 105.7M |
| EBT (Pre-Tax Income) | (43.4M) | (38.6M) | (6.8M) | (85.7M) | (122.5M) |
| Income Tax Expense | — | — | (3.0K) | (10.5M) | (17.9M) |
| Bottom Line | |||||
| Net Income | (43.4M) | (38.6M) | (6.8M) | (75.3M) | (104.6M) |
| Earnings from Cont. Ops | (43.4M) | (38.6M) | (6.8M) | (75.1M) | (104.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (43.4M) | (38.6M) | (6.8M) | (75.3M) | (104.6M) |
| Per Share | |||||
| Basic EPS | ($8.38) | ($4.18) | ($5.72) | ($3.70) | ($6.49) |
| Diluted EPS | ($8.38) | ($4.18) | ($5.72) | ($3.70) | ($6.49) |
| Revenue Per Share | $0.01 | $0.01 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 16.3M | 9.2M | 1.2M | 20.3M | 16.1M |
| Diluted Shares Outstanding | 16.3M | 9.2M | 1.2M | 20.3M | 16.1M |
| Profitability Metrics | |||||
| EBITDA | (32.8M) | (8.4M) | (6.7M) | (18.2M) | (122.3M) |
| D&A | 48.8K | 193.0K | 35.0K | 54.0K | 1.0K |
| EBIT | (32.9M) | (8.6M) | (6.8M) | (18.3M) | (122.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026